Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, Endpoints News reports

Core Insights - Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to reintroduce a compounded weight-loss pill after previously halting distribution due to U.S. regulatory concerns [1] - The compounded oral semaglutide pill is priced at $49, a version of Novo Nordisk's Wegovy, which was launched recently [1] - The move has faced backlash from Novo Nordisk and the U.S. FDA, leading to potential legal actions and regulatory scrutiny [1] Company Developments - Strive Pharmacy has not set a timeline for the reintroduction of the weight-loss pill, indicating a cautious approach while monitoring the regulatory environment [1] - Hims & Hers Health's decision to offer the compounded pill reflects a strategic move to enter the weight-loss market, despite the associated risks [1] Market Reactions - Following the news, shares of Novo Nordisk fell nearly 2%, while Eli Lilly's shares decreased by 1.7%, indicating market sensitivity to regulatory developments in the weight-loss drug sector [1]